{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:24:34Z","timestamp":1790177074351,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T00:00:00Z","timestamp":1369872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Malignant pleural mesothelioma (MPM) often develops decades following exposure to asbestos. Current best therapy produces a response in only half of patients, and the median survival with this therapy remains under a year. A search for novel targets and therapeutics is underway, and recently identified targets include VEGF, Notch, and EphB4-Ephrin-B2. Each of these targets has dual activity, promoting tumor cell growth as well as tumor angiogenesis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We investigated EphB4 expression in 39 human mesothelioma tissues by immunohistochemistry. Xenograft tumors established with human mesothelioma cells were treated with an EphB4 inhibitor (monomeric soluble EphB4 fused to human serum albumin, or sEphB4-HSA). The combinatorial effect of sEphB4-HSA and biologic agent was also studied.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>EphB4 was overexpressed in 72% of mesothelioma tissues evaluated, with 85% of epithelioid and 38% of sarcomatoid subtypes demonstrating overexpression. The EphB4 inhibitor sEphB4-HSA was highly active as a single agent to inhibit tumor growth, accompanied by tumor cell apoptosis and inhibition of PI3K and Src signaling. Combination of sEphB4-HSA and the anti-VEGF antibody (Bevacizumab) was superior to each agent alone and led to complete tumor regression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>EphB4 is a potential therapeutic target in mesothelioma. Clinical investigation of sEphB4-HSA as a single agent and in combination with VEGF inhibitors is warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-13-269","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T17:02:10Z","timestamp":1369933330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["EphB4 as a therapeutic target in mesothelioma"],"prefix":"10.1186","volume":"13","author":[{"given":"Ren","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kranthi","family":"Naga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parkash S","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Krasnoperov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,30]]},"reference":[{"issue":"1","key":"3896_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/sonc.2002.30227","volume":"29","author":"M Carbone","year":"2002","unstructured":"Carbone M, Kratzke RA, Testa JR: The pathogenesis of mesothelioma. Semin Oncol. 2002, 29 (1): 2-17.","journal-title":"Semin Oncol"},{"issue":"5","key":"3896_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2146\/ajhp110281","volume":"69","author":"SE Chen","year":"2012","unstructured":"Chen SE, Pace MB: Malignant pleural mesothelioma. Am J Health Syst Pharm. 2012, 69 (5): 377-385. 10.2146\/ajhp110281.","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"3896_CR3","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1245\/s10434-011-1728-x","volume":"18","author":"C Cao","year":"2011","unstructured":"Cao C, Yan TD, Bannon PG, McCaughan BC: Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol. 2011, 18 (10): 2973-2979. 10.1245\/s10434-011-1728-x.","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"3896_CR4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21 (14): 2636-2644. 10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3896_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","volume":"77","author":"JE Dowell","year":"2012","unstructured":"Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL: A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012, 77 (3): 567-571. 10.1016\/j.lungcan.2012.05.111.","journal-title":"Lung Cancer"},{"issue":"20","key":"3896_CR6","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE: Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012, 30 (20): 2509-2515. 10.1200\/JCO.2011.41.5869.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3896_CR7","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1242\/dev.129.6.1397","volume":"129","author":"SS Gerety","year":"2002","unstructured":"Gerety SS, Anderson DJ: Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development. 2002, 129 (6): 1397-1410.","journal-title":"Development"},{"issue":"3","key":"3896_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1097-2765(00)80342-1","volume":"4","author":"SS Gerety","year":"1999","unstructured":"Gerety SS, Wang HU, Chen ZF, Anderson DJ: Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell. 1999, 4 (3): 403-414. 10.1016\/S1097-2765(00)80342-1.","journal-title":"Mol Cell"},{"issue":"2","key":"3896_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1006\/dbio.2000.9957","volume":"230","author":"D Shin","year":"2001","unstructured":"Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, Isner J, Folkman J, Gimbrone MA, Anderson DJ: Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization. Dev Biol. 2001, 230 (2): 139-150. 10.1006\/dbio.2000.9957.","journal-title":"Dev Biol"},{"issue":"8","key":"3896_CR10","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood-2008-12-192294","volume":"114","author":"O Salvucci","year":"2009","unstructured":"Salvucci O, Maric D, Economopoulou M, Sakakibara S, Merlin S, Follenzi A, Tosato G: EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood. 2009, 114 (8): 1707-1716. 10.1182\/blood-2008-12-192294.","journal-title":"Blood"},{"issue":"7297","key":"3896_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature08995","volume":"465","author":"S Sawamiphak","year":"2010","unstructured":"Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, Acker-Palmer A: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 2010, 465 (7297): 487-491. 10.1038\/nature08995.","journal-title":"Nature"},{"issue":"19","key":"3896_CR12","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1182\/blood-2011-09-380006","volume":"119","author":"MA Abengozar","year":"2012","unstructured":"Abengozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda D, Marenchino M, Canamero M, Ortega S, Megias D, Rodriguez A, Martinez-Torrecuadrada JL: Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood. 2012, 119 (19): 4565-4576. 10.1182\/blood-2011-09-380006.","journal-title":"Blood"},{"issue":"7297","key":"3896_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature09002","volume":"465","author":"Y Wang","year":"2010","unstructured":"Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Luthi U, Barberis A, Benjamin LE, Makinen T, Nobes CD, Adams RH: Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010, 465 (7297): 483-486. 10.1038\/nature09002.","journal-title":"Nature"},{"issue":"1","key":"3896_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2008-02-140020","volume":"113","author":"JS Scehnet","year":"2009","unstructured":"Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS: The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood. 2009, 113 (1): 254-263. 10.1182\/blood-2008-02-140020.","journal-title":"Blood"},{"issue":"1","key":"3896_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2353\/ajpath.2006.050889","volume":"169","author":"SR Kumar","year":"2006","unstructured":"Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, Kumar NG, Hawes D, Press MF, Weaver FA, Gill PS: Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006, 169 (1): 279-293. 10.2353\/ajpath.2006.050889.","journal-title":"Am J Pathol"},{"issue":"11","key":"3896_CR16","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1158\/0008-5472.CAN-04-2667","volume":"65","author":"G Xia","year":"2005","unstructured":"Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS: EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005, 65 (11): 4623-4632. 10.1158\/0008-5472.CAN-04-2667.","journal-title":"Cancer Res"},{"issue":"7","key":"3896_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/sj.bjc.6603642","volume":"96","author":"SR Kumar","year":"2007","unstructured":"Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS: The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer. 2007, 96 (7): 1083-1091. 10.1038\/sj.bjc.6603642.","journal-title":"Br J Cancer"},{"issue":"1","key":"3896_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/BF02893405","volume":"10","author":"Q Wu","year":"2004","unstructured":"Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM: Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res. 2004, 10 (1): 26-33. 10.1007\/BF02893405.","journal-title":"Pathol Oncol Res"},{"key":"3896_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1471-2407-5-119","volume":"5","author":"YC Lee","year":"2005","unstructured":"Lee YC, Perren JR, Douglas EL, Raynor MP, Bartley MA, Bardy PG, Stephenson SA: Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma. BMC Cancer. 2005, 5: 119-10.1186\/1471-2407-5-119.","journal-title":"BMC Cancer"},{"issue":"8","key":"3896_CR20","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/1535-7163.MCT-10-0200","volume":"9","author":"WA Spannuth","year":"2010","unstructured":"Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK: Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010, 9 (8): 2377-2388. 10.1158\/1535-7163.MCT-10-0200.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3896_CR21","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ijc.21926","volume":"119","author":"R Masood","year":"2006","unstructured":"Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schonthal AH, Gill PS: EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer. 2006, 119 (6): 1236-1248. 10.1002\/ijc.21926.","journal-title":"Int J Cancer"},{"issue":"10","key":"3896_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/archotol.132.10.1053","volume":"132","author":"UK Sinha","year":"2006","unstructured":"Sinha UK, Mazhar K, Chinn SB, Dhillon VK, Liu L, Masood R, Rice DH, Gill PS: The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006, 132 (10): 1053-1059. 10.1001\/archotol.132.10.1053.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"1","key":"3896_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/0008-5472.CAN-12-0915","volume":"73","author":"R Hasina","year":"2013","unstructured":"Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R: Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers. Cancer Res. 2013, 73 (1): 184-194. 10.1158\/0008-5472.CAN-12-0915.","journal-title":"Cancer Res"},{"issue":"12","key":"3896_CR24","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/1078-0432.CCR-04-2109","volume":"11","author":"G Xia","year":"2005","unstructured":"Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS: Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res. 2005, 11 (12): 4305-4315. 10.1158\/1078-0432.CCR-04-2109.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3896_CR25","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/sj.emboj.7601031","volume":"25","author":"A Georgakopoulos","year":"2006","unstructured":"Georgakopoulos A, Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK: Metalloproteinase\/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. EMBO J. 2006, 25 (6): 1242-1252. 10.1038\/sj.emboj.7601031.","journal-title":"EMBO J"},{"issue":"4","key":"3896_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1097-2765(02)00488-4","volume":"9","author":"A Palmer","year":"2002","unstructured":"Palmer A, Zimmer M, Erdmann KS, Eulenburg V, Porthin A, Heumann R, Deutsch U, Klein R: EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol Cell. 2002, 9 (4): 725-737. 10.1016\/S1097-2765(02)00488-4.","journal-title":"Mol Cell"},{"issue":"4","key":"3896_CR27","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2353\/ajpath.2010.090755","volume":"176","author":"V Krasnoperov","year":"2010","unstructured":"Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS: Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit Tumor Growth. Am J Pathol. 2010, 176 (4): 2029-2038. 10.2353\/ajpath.2010.090755.","journal-title":"Am J Pathol"},{"issue":"6","key":"3896_CR28","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1182\/blood-2005-04-1655","volume":"107","author":"N Kertesz","year":"2006","unstructured":"Kertesz N, Krasnoperov V, Reddy R, Leshanski L, Kumar SR, Zozulya S, Gill PS: The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood. 2006, 107 (6): 2330-2338. 10.1182\/blood-2005-04-1655.","journal-title":"Blood"},{"issue":"6","key":"3896_CR29","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/jps.23096","volume":"101","author":"S Shi","year":"2012","unstructured":"Shi S, Liu J, Joshi SB, Krasnoperov V, Gill P, Middaugh CR, Volkin DB: Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. J Pharm Sci. 2012, 101 (6): 1969-1984. 10.1002\/jps.23096.","journal-title":"J Pharm Sci"},{"issue":"1","key":"3896_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1186\/1471-2407-10-641","volume":"10","author":"D Djokovic","year":"2010","unstructured":"Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, Liu R, Li X, Gong M, Krasnoperov V, Gill PS, Duarte A: Combination of Dll4\/Notch and Ephrin-B2\/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer. 2010, 10 (1): 641-10.1186\/1471-2407-10-641.","journal-title":"BMC Cancer"},{"issue":"2","key":"3896_CR31","first-page":"181","volume":"2","author":"Y Suzuki","year":"2009","unstructured":"Suzuki Y, Murakami H, Kawaguchi K, Tanigushi T, Fujii M, Shinjo K, Kondo Y, Osada H, Shimokata K, Horio Y, Hasegawa Y, Hida T, Sekido Y: Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Report. 2009, 2 (2): 181-188.","journal-title":"Mol Med Report"},{"issue":"1","key":"3896_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/CAD.0b013e32833f44fd","volume":"22","author":"W Zhao","year":"2011","unstructured":"Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y, Xu Q: Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs. 2011, 22 (1): 79-88. 10.1097\/CAD.0b013e32833f44fd.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"3896_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ijc.10996","volume":"104","author":"R Masood","year":"2003","unstructured":"Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL, Gill PS: Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer. 2003, 104 (5): 603-610. 10.1002\/ijc.10996.","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-269\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:04:48Z","timestamp":1630541088000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,30]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3896"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-269","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,30]]},"assertion":[{"value":"11 January 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"269"}}